| Literature DB >> 33329301 |
Leah H Rubin1,2,3, Erin E Sundermann4, Raha Dastgheyb1, Alison S Buchholz2, Elizabeth Pasipanodya4,5, Robert K Heaton4, Igor Grant4, Ronald Ellis4,6, David J Moore4.
Abstract
Despite advancements in antiretroviral therapy, mild cognitive deficits persist in nearly half of people with HIV (PWH). The profile of impairment in HIV is highly variable with deficits observed in a range of cognitive domains. Despite evidence of greater cognitive impairment among women with HIV (WWH) vs. men with HIV (MWH), it is unclear how MWH and WWH differ in the type of cognitive impairment and in risk factors associated with cognitive impairment profiles. In a large and well-characterized sample of PWH, we used machine learning to identify profiles of cognitive functioning and their associated factors overall and within sex. Participants included 1,666 PWH (201 WWH; 1,465 MMH) from the HIV Neurobehavioral Research Program who completed a neuropsychological test battery at their baseline visits. Using demographically-adjusted T-scores from 13 test outcomes assessing motor skills, executive functioning, attention/working memory, episodic learning and memory, verbal fluency, and processing speed, we used Kohonen self-organizing maps to identify patterns of high-dimensional data by mapping participants to similar nodes based on T-scores (MCLUST R package). Random forest models were used to determine how sociodemographic (e.g., age, education), clinical (e.g., depressive symptoms, substance use disorder), and biological (e.g., HIV disease characteristics) factors differentially related to membership within a cognitive profile. All analyses were repeated within sex. Three cognitive profiles were identified overall and within each sex. Overall and within MWH, there were unimpaired and global weakness profiles. The third profile in the total sample demonstrated relatively weak auditory attention whereas in MWH showed relative strengths in attention and processing speed. Conversely, there was no unimpaired profile among WWH. Rather, WWH demonstrated separate profiles reflecting weakness in motor skills, a relative weakness in learning and delayed recall, and global weaknesses with spared recognition memory. Despite different cognitive profiles by sex, the most discriminative factors were similar between men and women and included reading level (cognitive reserve), current and nadir CD4 count, plasma HIV viral load, duration of HIV disease, age, depressive symptoms, and race/ethnicity. Findings fill a knowledge gap concerning sex differences in cognitive impairment in PWH and inform personalized risk reduction and therapeutic strategies.Entities:
Keywords: HIV; cognition; cognitive profiles; neuropsychology; sex differences; women
Year: 2020 PMID: 33329301 PMCID: PMC7732436 DOI: 10.3389/fneur.2020.551921
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Demographic, behavioral, and clinical characteristics in the total sample of people with HIV and by sex.
| Age, M (SD) | 41.7 (9.8) | 41.9 (9.8) | 40.7 (9.6) | 0.09 |
| Years of education, M (SD) | 13.3 (2.7) | 13.5 (2.7) | 12.0 (2.5) | <0.001 |
| WRAT-4, M (SD) | 99.1 (13.5) | 99.8 (13.3) | 93.5 (13.2) | <0.001 |
| Race | <0.001 | |||
| White | 971 (58) | 890 (61) | 81 (40) | |
| Black | 314 (19) | 259 (18) | 55 (28) | |
| Hispanic | 299 (18) | 246 (17) | 53 (26) | |
| Other | 82 (5) | 70 (4) | 12 (6) | |
| IADL dependence | 2.5 (2.9) | 2.4 (2.8) | 2.9 (3.1) | 0.03 |
| BDI-II | 13.5 (10.4) | 13.5 (10.4) | 13.5 (9.9) | 0.99 |
| DSM-IV (CIDI) diagnoses | ||||
| MDD | ||||
| Current | 224 (19) | 203 (19) | 21 (18) | 0.94 |
| Lifetime | 572 (48) | 510 (48) | 572 (48) | 0.24 |
| Alcohol (current or lifetime | 72 (6) | 66 (6) | 6 (5) | 0.84 |
| Cannabis (current or lifetime | 63 (5) | 60 (6) | 3 (3) | 0.25 |
| Substance use (current or lifetime | 691 (73) | 627 (73) | 64 (71) | 0.74 |
| Anticholinergic medications | 422 (25) | 367 (25) | 55 (27) | 0.53 |
| Hypertension | 334 (21) | 298 (21) | 36 (18) | 37 |
| Hyperlipidemia | 219 (14) | 193 (14) | 26 (13) | 0.9 |
| Diabetes | 82 (5) | 70 (5) | 12 (6) | 0.64 |
| HCV | 317 (20) | 259 (18) | 58 (29) | <0.001 |
| Log plasma viral load, M (SD) | 3.1 (1.3) | 3.1 (1.3) | 3.1 (1.2) | 0.83 |
| CD4 count, M (SD) | ||||
| Current | 429.0 (296.9) | 426.9 (295.8) | 443.7 (305.3) | 0.46 |
| Nadir | 229.9 (219.9) | 250.4 (231.8) | 232.4 (221.4) | 0.21 |
| Duration of HIV disease, M (SD) | 9.1 (7.8) | 9.3 (8.0) | 7.0 (5.6) | 0.005 |
| AIDS diagnosis | 969 (58) | 854 (59) | 115 (57) | 0.07 |
| On ART | 966 (60) | 857 (60) | 109 (56) | 0.3 |
M, mean; SD, standard deviation; ART, antiretroviral therapy; WRAT-4, Wide Range Achievement Test; IADL, Instrumental Activities of Daily Living; BDI, Beck depression inventory; CIDI, Composite International Diagnostic Interview; HCV, Hepatitis C.
Current or Lifetime Use disorder (abuse or dependence).
Neuropsychological test performance in the total sample of people with HIV and by sex.
| Total learning | 45.4 (10.0) | 45.6 (10.1) | 43.84 (9.6) | 0.01 |
| Delayed recall | 42.2 (11.4) | 45.2 (11.5) | 45.6 (11.1) | 0.6 |
| Recognition | 45.8 (13.7) | 45.5 (13.7) | 48.3 (13.1) | 0.006 |
| Total learning | 42.6 (11.6) | 42.5 (11.7) | 43.0 (11.1) | 0.56 |
| Delayed recall | 43.2 (11.7) | 43.3 (11.8) | 42.6 (10.8) | 0.41 |
| Recognition | 44.4 (13.8) | 43.6 (13.6) | 50.5 (13.3) | <0.001 |
| Dominant | 45.4 (11.9) | 45.4 (11.8) | 45.4 (12.5) | 0.98 |
| Non-dominant | 44.7 (11.3) | 44.7 (11.3) | 44.4 (11.6) | 0.7 |
| Part A | 48.3 (11.9) | 48.2 (11.9) | 49.1 (11.7) | 0.31 |
| Part B | 46.3 (11.7) | 46.1 (11.7) | 47.4 (11.4) | 0.14 |
| Letter fluency | 47.0 (11.5) | 47.0 (11.2) | 46.9 (13.2) | 0.96 |
| PASAT 50 | 44.7 (11.6) | 44.7 (11.6) | 44.9 (11.8) | 0.79 |
| Digit symbol test | 47.2 (11.2) | 47.3 (11.3) | 46.9 (10.7) | 0.67 |
| Total learning | 429 (29) | 499 (30) | 70 (34) | 0.13 |
| Delayed recall | 483 (33) | 546 (33) | 63 (31) | 0.70 |
| Recognition | 434 (30) | 487 (29) | 53 (26) | 0.38 |
| Total learning | 595 (41) | 670 (40) | 75 (37) | 0.41 |
| Delayed recall | 564 (38) | 641 (38) | 77 (38) | 1.00 |
| Recognition | 476 (33) | 510 (31) | 34 (17) | <0.001 |
| Dominant | 470 (32) | 536 (32) | 66 (33) | 0.89 |
| Non-dominant | 461 (31) | 523 (31) | 62 (31) | 0.92 |
| Part A | 297 (20) | 341 (20) | 44 (22) | 0.66 |
| Part B | 410 (28) | 457 (27) | 47 (23) | 0.20 |
| Letter fluency | 342 (23) | 396 (24) | 54 (27) | 0.31 |
| PASAT 50 | 508 (35) | 580 (35) | 72 (36) | 0.81 |
| Digit symbol test | 378 (26) | 430 (26) | 52 (26) | 1.00 |
M, mean; SD, standard deviation; BVMT-R, Benton Visual Retention Test-Revised; HVLT-R, Hopkins Verbal Learning Test-Revised; PASAT, Paced Auditory Serial Addition Test.
Figure 1Profiling results in the (A) Total sample, (B) Men with HIV, and (C) Women with HIV. The small dotted line indicates a half of a standard deviation above and below the mean whereas the large dotted line indicates a full standard deviation above and below the mean. BVMT, Brief Visuospatial Memory Test-Revised; HVLT, Hopkins Verbal Learning Test Revised; PASAT, Paced Auditory Serial Addition Task; TMT, Trail Making Test; GPEG, Grooved pegboard.
Figure 2Percent impairment (T-score cutoff of 40) for each profile in the (A) Total sample, (B) Men with HIV, and (C) Women with HIV. BVMT, Brief Visuospatial Memory Test-Revised; HVLT, Hopkins Verbal Learning Test Revised; PASAT, Paced Auditory Serial Addition Task; TMT, Trail Making Test; GPEG, Grooved pegboard.
Figure 3Random forest variable importance from the models for (A) Total sample, (B) Men with HIV, and (C) Women with HIV. IADL, Instrumental Activities of Daily Living; WRAT, Wide Range Achievement Test-4 Reading subtest; BDI, Beck Depression Inventory; LT, lifetime; HCV, Hepatitis C co-infectious; MDD, major depressive disorder.
Demographic, behavioral, and clinical characteristics in the total sample of people with HIV by cognitive profile.
| Age, M (SD) | 41.2 (9.1) | 39.4 (9.4) | 44.2(10.2) | <0.001 |
| Male | 544 (88) | 401 (87) | 520 (89) | 0.73 |
| Years of education, M (SD) | 13.5 (2.5) | 12.9 (2.7) | 13.5 (2.8) | <0.001 |
| WRAT-4, M (SD) | 102.2 (11.9) | 96.5 (13.6) | 97.6 (14.2) | <0.001 |
| Race | <0.001 | |||
| White | 387 (63) | 202 (44) | 382 (65) | |
| Black | 119 (19) | 104 (23) | 91 (15) | |
| Hispanic | 76 (12) | 132 (29) | 91 (15) | |
| Other | 36 (6) | 23 (5) | 23 (4) | |
| IADL dependence | 2.2 (2.7) | 2.2 (2.7) | 3.0 (3.1) | <0.001 |
| BDI-II | 12.4 (9.9) | 13.4 (10.8) | 14.7(10.4) | <0.001 |
| MDD | ||||
| Current | 67 (17) | 59 (16) | 98 (22) | 0.06 |
| Lifetime | 198 (51) | 154 (43) | 220 (50) | 0.05 |
| Alcohol (current or lifetime | 19 (5) | 25 (7) | 28 (6) | 0.47 |
| Cannabis (current or lifetime | 23 (6) | 21 (6) | 19 (4) | 0.52 |
| Substance use (current or lifetime | 232 (76) | 208 (72) | 251 (71) | 0.41 |
| Anticholinergic medication | 127 (21) | 125 (27) | 170 (29) | 0.002 |
| Hypertension | 123 (21) | 71 (16) | 140 (25) | 0.002 |
| Hyperlipidemia | 82 (14) | 44 (10) | 93 (16) | 0.008 |
| Diabetes | 38 (6) | 14 (3) | 30 (5) | 0.05 |
| HCV | 111 (19) | 81 (18) | 125 (22) | 0.18 |
| Log plasma viral load, M (SD) | 3.2 (1) | 3.0 (1.3) | 3.1 (1.4) | 0.05 |
| CD4 count, M (SD) | ||||
| Current | 434.6 (283.1) | 449.9 (305.6) | 406 (303.5) | 0.05 |
| Nadir | 245.1 (214.7) | 259.8 (251.2) | 197.5 (198.3) | <0.001 |
| Duration of HIV disease, M (SD) | 8.9 (7.8) | 7.9 (7.2) | 10.2 (8.2) | <0.001 |
| AIDS diagnosis | 331 (54) | 253 (55) | 385 (66) | <0.001 |
| On ART | 322 (54) | 275 (61) | 369 (65) | <0.001 |
ART, antiretroviral therapy; WRAT-4, Wide Range Achievement Test-4th edition; IADL, Instrumental Activities of Daily Living; BDI, Beck depression inventory; CIDI, Composite International Diagnostic Interview; HCV, Hepatitis C;
Current or Lifetime Use disorder (abuse or dependence).
Demographic, behavioral, and clinical characteristics in the sample of men with HIV by cognitive profile.
| Age, M (SD) | 40.6 (9.1) | 41.9 (9.8) | 44.3(10.6) | <0.001 |
| Years of education, M (SD) | 13.4 (2.52) | 13.7 (2.6) | 13.6 (2.9) | 0.245 |
| WRAT-4, M (SD) | 99.7 (12.8) | 104.1 (11.8) | 96.8 (14.5) | <0.001 |
| Race | 0.01 | |||
| White | 432 (57) | 188 (66) | 270 (63) | |
| Black | 146 (19) | 48 (17) | 65 (15) | |
| Hispanic | 139 (19) | 31 (11) | 76 (18) | |
| Other | 36 (5) | 19 (6) | 15 (4) | |
| IADL complaints | 2.2 (2.7) | 1.4 (1.9) | 3.4 (3.3) | <0.001 |
| BDI | 13.1 (10.4) | 10.5 (9.) | 16.2 (10.7) | <0.001 |
| MDD | ||||
| Current | 105 (19) | 21 (10) | 77 (24) | <0.001 |
| Lifetime | 259 (47) | 92 (45) | 159 (49) | 0.66 |
| Alcohol (current or lifetime | 40 (7) | 3 (1) | 23 (7) | 0.009 |
| Cannabis (current or lifetime | 36 (7) | 8 (4) | 16 (5) | 0.31 |
| Substance use (current or lifetime | 321 (74) | 121 (73) | 183 (72) | 0.90 |
| Anticholinergic medication | 195 (26) | 48 (17) | 124 (29) | <0.001 |
| Hypertension | 140 (19) | 51 (19) | 107 (26.) | 0.01 |
| Hyperlipidemia | 96 (13) | 40 (15) | 57 (14) | 0.82 |
| Diabetes | 40 (5) | 8 (3) | 22 (5) | 0.22 |
| HCV | 125 (17) | 46 (17) | 88 (21) | 0.14 |
| Log plasma viral load, M (SD) | 3.2 (1.3) | 2.9 (1.3) | 3.2 (1.5) | 0.01 |
| Current | 432.4 (301.1) | 479.0 (272.8) | 381.4 (295.0) | <0.001 |
| Nadir | 238.6 (232.8) | 268.2 (209.8) | 188.8 (196.1) | <0.001 |
| Duration of HIV disease, M (SD) | 8.9 (7.8) | 8.5 (7.4) | 10.4 (8.6) | 0.01 |
| AIDS diagnosis | 440 (56) | 113 (47) | 281 (66) | <0.001 |
| On ART | 426 (58) | 166 (59) | 265 (64) | 0.10 |
ART, antiretroviral therapy; WRAT-4, Wide Range Achievement Test; IADL, Instrumental Activities of Daily Living; BDI, Beck depression inventory; CIDI, Composite International Diagnostic Interview; HCV, Hepatitis C;
Current or Lifetime Use disorder (abuse or dependence).
Demographic, behavioral, and clinical characteristics in the sample of women with HIV by cognitive profile.
| Age, M (SD) | 37.4 (8.5) | 42.4 (9.9) | 41.9 (9.8) | 0.005 |
| Years of education, M (SD) | 11.5 (2.5) | 12.6 (2.4) | 11.9 (2.6) | 0.03 |
| WRAT-4, M (SD) | 96.6 (9.8) | 95.5 (13.9) | 88.9 (13.5) | 0.003 |
| Race | 0.007 | |||
| White | 21 (33) | 32 (46) | 28 (42) | |
| Black | 16 (25) | 26 (37) | 13 (19) | |
| Hispanic | 25 (39) | 8 (11) | 20 (30) | |
| Other | 2 (3) | 4 (6) | 6 (9) | |
| IADL dependence | 2.7 (3.0) | 2.2 (2.7) | 3.8 (3.5) | 0.01 |
| BDI-II | 13.7 (9.5) | 10.9 (9.2) | 16.0 (10.5) | 0.01 |
| MDD | ||||
| Current | 5 (14) | 2 (5) | 14 (34) | 0.003 |
| Lifetime | 17 (47) | 17 (45) | 28 (68) | 0.06 |
| Alcohol (current or lifetime | 3 (8) | 2 (5) | 1 (2) | 0.51 |
| Cannabis (current or lifetime | 1 (3) | 2 (5) | 0 (0) | 0.34 |
| Substance use (current or lifetime | 22 (81) | 21 (66) | 21 (67) | 0.36 |
| Anticholinergic medication | 16 (25) | 18 (26) | 21 (31) | 0.66 |
| Hypertension | 8 (12) | 16 (23) | 12 (18) | 0.28 |
| Hyperlipidemia | 5 (8) | 9 (13) | 12 (18) | 0.21 |
| Diabetes | 5 (8) | 2 (3) | 58 | 0.4 |
| HCV | 22 (34) | 18 (26) | 18 (27) | 0.53 |
| Log plasma viral load, M (SD) | 3.1 (0.9) | 3.1 (1.2) | 3.2 (1.3) | 0.72 |
| CD4 count, M (SD) | ||||
| Current | 448.4 (282.9) | 516.5 (309.6) | 358.2 (304.7) | 0.01 |
| Nadir | 298.6 (269.1) | 273.1 (232.0) | 181.3 (173.5) | 0.009 |
| Duration of HIV disease, M (SD) | 7.3 (5.4) | 7.41 (6.1) | 6.5 (5.3) | 0.76 |
| AIDS diagnosis | 32 (50) | 36 (51) | 47 (70) | 0.03 |
| On ART | 34 (55) | 36 (52) | 39 (61) | 0.58 |
ART, antiretroviral therapy; WRAT-4, Wide Range Achievement Test; IADL, Instrumental Activities of Daily Living; BDI, Beck depression inventory; CIDI, Composite International Diagnostic Interview; HCV, Hepatitis C;
Current or Lifetime Use disorder (abuse or dependence).